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1. Introduction 
Age-related macular degeneration (AMD) is one of the leading causes of substantial and 
irreversible vision loss. The prevalence of AMD can be expected to increase along with life 
expectancy, which has risen steadily [1, 2]. Without treatment, the neovascular form of AMD 
leads to severe quality-of-life loss within a short time period and considerable economic burden.  
Vascular endothelial growth factor (VEGF) is a key mediator involved in the control of 
angiogenesis and vascular permeability and has been shown to be induced by hypoxia in 
cultured human retinal pigment epithelium (RPE) [3]. VEGF-A is the most potent promoter 
of angiogenesis and vascular permeability within the VEGF family and its role in the 
pathogenesis of neovascular AMD is well recognized [4, 5]. The advent of intravitreous 
VEGF inhibitors has revolutionized the management of neovascular AMD. Yet, frequently, 
indefinite injections of VEGF blocking agents introduce a significant treatment burden for 
patients with neovascular AMD, and may potentially put patients in the risk of developing 
ocular and systemic adverse effects from injections. Many studies on modified treatment 
regimens have been performed in an attempt to mitigate this burden without compromise to 
visual acuity outcomes. Meanwhile, various randomized clinical trials on combination 
therapies and efforts to develop new pharmacologic agents are ongoing.  
2. Therapeutic monoclonal antibodies and fragments  
2.1 Intravitreal ranibizumab and bevacizumab monotherapy  
2.1.1 Vascular endothelial growth factor  
VEGF plays an important role in a variety of in vitro processes, including angiogenesis, 
microvascular permeability, and endothelial cell survival. On the other hand, these activities are 
all essential to survival, VEGF has been linked to a number of pathogenic conditions, including 
neovascular AMD, diabetic retinopathy, and cancer. 
Three VEGF therapies are currently used for the treatment of patients with neovascular 
AMD: pegaptanib (Macugen, OSI Pharmaceuticals, USA), ranibizumab (Lucentis, 
Genentech, USA), and bevacizumab (Avastin, Genentech, USA).  
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Pegaptanib is an oligonucleotide aptamer and was the first VEGF antagonist to be approved 
by the US Food and Drug Administration (FDA) for use in wet AMD. However, wet AMD 
patients treated with pegaptanib still experience visual decline. [2, 6] The first monoclonal 
antibody developed to target VEGF was bevacizumab, a humanized murine monoclonal 
antibody. Bevacizumab was initially developed for applications in oncology, and received 
approval as a first-line therapy for widespread colorectal cancer from the US FDA in 2004. 
Bevacizumab has subsequently been approved for use in non-small cell lung cancer and 
breast cancer.  
The successful development of VEGF as an oncology target led to interest in the potential of 
anti-VEGF treatment for other therapeutic indications, including ocular neovascular 
disorders. VEGF-A has been identified as the primary angiogenesis mediator in the eye. It is 
implicated in ocular neovascularization through its promotion of blood vessel formation 
and permeability. A role for VEGF-A in neovascular AMD is suggested by 
immunohistochemistry localization in human choroidal neovascular (CNV) lesions and 
extrapolation from other disease models [5, 7-9].  
New blood vessel formation and leakage play important roles in the development of the 
neovascular form of AMD, and clinical trials of agents that block VEGF-A activity have 
produced more evidence that VEGF-A is important in development of this disease.  
Ranibizumab is a humanized antibody fragment against VEGF which was specifically 
designed for intraocular use as a smaller antibody fragment to penetrate through the retina 
better. The Food and Drug Administration (FDA) approved ranibizumab for treatment of 
subfoveal neovascular AMD in June, 2006. It was the first drug for AMD treatment shown to 
improve visual acuity in a substantial percentage of patients.  
Bevacizumab is a recombinant humanized monoclonal immunoglobulin antibody that 
inhibits the activity of VEGF. It has a similar action and is related to the ranibizumab 
compound with respect to its structure. Bevacizumab was approved by the FDA for the 
treatment of metastatic colorectal cancer in 2004, but it has not been licensed for the 
treatment of wet AMD or any other ocular conditions. However, it is recently used off-label 
worldwide not only for wet AMD but also for other ocular disease entities associated with 
macular edema and abnormal vessel growth.  
Intraocular pharmacokinetic data derived from studies in monkeys demonstrated that 
through intravitreal administration, ranibizumab distributed rapidly to the retina and had a 
vitreous half-life of 3 days. Studies in rabbits have demonstrated that ranibizumab can 
rapidly penetrate through the retina to reach the choroid, just 1 hr after intravitreal 
admidistration [10]. In primates, serum ranibizumab levels were found to be more than 
1000-fold lower than in the vitreous and aquous humor following a single intravitreal 
injection [11]. These were negligible and tissue concentrations were undetectable.  
2.1.2 Safety 
Systemic VEGF inhibition is suspected to be associated with an increased risk of 
hypertension and arterial thromboembolic events. Given the average age of patients 
requiring treatment for AMD, it is important that their treatment does not significantly 
increase the risk of these events. The rate of arterial thromboembolic events and 
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hypertension was low. Over the 24 months trial period, the rates in the ranibizumab 0.5 mg 
treatment group of the ANCHOR, MARINA, and PIER trials was 5.0 %, 4.6 %, and 0 %, 
respectively, compared with 4.2 %, 3.8 %, and 0 % in the control group. 
2.1.3 Efficacy  
The pivotal phase III Minimally Classic/Occult Trial of the Anti-VEGF Antibody 
Ranibizumab in the Treatment of Neovascular AMD (MARINA) [12] and the Anti-VEGF 
Antibody for the Treatment of Predominantly Classic CNV in AMD (ANCHOR) trial  
[13, 14] demonstrated best-corrected visual acuity (BCVA) outcomes were far superior  
to any previously published study in the treatment of this disease. At the end of 24 months 
in the MARINA trial, significantly more ranibizumab-treated patients had maintained  
[lost <15 Early Treatment Diabetic Retinopathy Study (ETDRS) letters] or improved vision 
than sham-injected patients. Indeed, 90–95% of patients treated with 0.3 and 0.5 mg 
ranibizumab maintained vision compared with 53–64% of control patients. Over the same 
period, vision improved in 25–34% of treated eyes, compared with 4–5% of sham-injected 
patients.  
In the ANCHOR trial, ranibizumab was compared with verteporfin photodynamic therapy 
(PDT) and demonstrated similar findings: 90–96% of the ranibizumab-treated versus 64–66% 
of the PDT-treated patients maintained vision, whereas 34–41% versus 6% of each group, 
respectively, gained more than 15 letters.  
These outcomes were significantly better than those achieved by the control groups. 
In both trials, a biphasic treatment effect was observed, with the majority of the visual gain 
achieved in the first 3 months of treatment (the loading phase) followed by stabilization of 
the gain (the maintenance phase).  
Patient-reported outcomes were also assessed in the ANCHOR and MARINA trials to 
measure the influence of the ranibizumab-mediated improvement in visual acuity (VA) on 
quality of life. The data demonstrated that patients treated with ranibizumab were more 
likely to report improvements in near activities, distance activities, and vision specific 
dependency which were maintained over the 2 year duration of the trial [15, 16]. These data 
demonstrate that the clinical improvements seen with ranibizumab treatment translate into 
meaningful benefits for the patient.  
More recently, the anatomical benefit of ranibizumab treatment in both the MARINA and 
ANCHOR studies with regard to angiographic and optical coherence tomography (OCT) 
characteristics has also been demonstrated. [12, 15, 16] Both functional and anatomical 
improvements were maintained over the 24 month study period with monthly injections. 
Bevacizumab, the predecessor of ranibizumab, is a full-length monoclonal antibody that 
binds to and blocks the action of all VEGF isoforms. Numerous retrospective [17-20] and 
prospective studies [21-23] of intravitreal bevacizumab have reported its efficacy for 
neovascular AMD and low rates of treatment related complications [24]. Although a number 
of these studies were uncontrolled, relatively small in sample size, of limited follow-up, and 
varied with regard to outcome measures and retreatment criteria, the reported efficacy of 
bevacizumab coupled with its low cost when utilized as an intraocular agent has propelled 
its adoption worldwide.  
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A recent, large, multicenter, randomized prospective study (Bevacizumab for Neovascular 
Age-Related Macular Degeneration [ABC] trial) that demonstrated MARINA/ANCHOR-
like results lends further support for its use in neovascular AMD [25, 26]. On the basis of 
results from the pivotal phase III clinical trials, ranibizumab dosed monthly represents the 
gold standard to which all other therapeutics and regimens are to be compared. In clinical 
practice, many retinal physicians have extrapolated the data and continued using 
bevacizumab. A formal head-to-head comparison of bevacizumab and ranibizumab is being 
conducted by the National Eye Institute of the National Institute of Health in the 
Comparisons of Age-Related Macular Degeneration Treatment Trials (CATTs) [27, 28]. The 
CATT study design includes four treatment arms: either bevacizumab or ranibizumab on a 
variable schedule means that monthly follow-up and evaluation of fluid based on OCT, and 
anti-VEGF injection when CNV becomes active and either bevacizumab or ranibizumab on a 
fixed monthly schedule for 1 year followed by random assignment to either continued 
monthly injections or a variable schedule based on the treatment response. The primary 
outcome measure is mean change in BCVA; secondary outcome measures include number 
of treatments, anatomical changes in the retina, adverse events, and cost. Preliminary results 
are reported in 2011 and will provide insight into how ranibizumab and bevacizumab 
compare with each other within the context of either a fixed monthly or traditional pro re 
nata (PRN) approach. At 1 year, bevacizumab and ranibizumab had equivalent effects on 
VA when administered according to the same schedule. Bevacizumab administered 
monthly was equivalent to ranibizumab administered monthly, with 8.0 and 8.5 letters 
gained, respectively. Bevacizumab administered as needed was equivalent to ranibizumab 
as needed, with 5.9 and 6.8 letters gained, respectively. Ranibizumab given as needed with 
monthly evaluation had effects on vision that were equivalent to those of ranibizumab 
administered monthly, although the comparison between bevacizumab as needed and 
monthly bevacizumab was inclusive. Differences in rate of serious adverse events require 
further study.  
3. Modified treatment regimens 
The prospect of indefinitely adhering to the monthly treatment schedules of MARINA and 
ANCHOR has raised ocular and systemic safety concerns as well as convenience and cost issues 
for patient and physician alike. The identification of alternative dosing strategies capable of 
reducing the number of required anti-VEGF injections while still achieving VA outcomes 
similar to those reached in the pivotal trials has since been a subject of great interest.  
The observed biphasic treatment effect raised the possibility that, after the initial  
3-months loading phase, maintenance of VA gain may be achieved with less frequent 
treatments. A PIER trial evaluated ranibizumab administered monthly for 3 months, 
followed by quarterly injections, and compared this with sham treatment. Under this 
schedule, ranibizumab did provide a significant VA benefit; a significantly greater 
number of patients achieved VA stabilization at 24 months compared with patients 
receiving sham treatment. However, subgroup analysis revealed that VA gains observed 
during the first 3 months of treatment were only maintained in 40% of patients over the 
duration of the trial, and for the remaining 60% quarterly dosing was not suitable [29, 30]. 
Results for both ranibizumab doses in the PIER trial (0.3 and 0.5mg) showed an initial 
mean improvement in BCVA during the initiation phase with monthly dosing, but after 
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month 3 in the maintenance phase with quarterly dosing, there was a gradual decline in 
mean BCVA to below the pretreatment baseline (2.2 letters) at 12 months, which remained 
unchanged at 24 months [30].  
More recently, the Efficacy and Safety of Ranibizumab in Patients with Subfoveal Choroidal 
Neovascularization Secondary to Age-Related Macular Degeneration (EXCITE) study 
directly compared the PIER regimen with a fixed monthly treatment arm (0.3 mg 
ranibizumab) [31]. Although BCVA outcomes in the two quarterly treatment arms fared 
better than those in the PIER study at 12 months (2.2 and 3.1 letters gain with 0.3 and 0.5 mg 
ranibizumab, respectively), neither was as good as monthly dosing (0.9 letters gain). These 
suboptimal results demonstrate that, on average, quarterly treatment is inferior to monthly 
treatment; thus, it has never been adopted in practice.  
Subsequently to the PIER trial, further investigation of a flexible dosing approach was 
carried out. The EXCITE trial directly compared a maintenance phase of quarterly injections 
against the monthly regimen. Consistent with previous observations, an initial gain was 
made in the first 3 months, after which patients receiving monthly injections contributed to 
gain VA, whilst those receiving quarterly injections showed a decrease from their 3 months 
VA levels. (Table 1.) 
 
 
Study design MARINA ANCHOR PIER EXCITE 
Study duration 24 months 24 months 24 months 12 months 
Number of patients 716 423 184 353 
Visit regimen in 
maintenance phase 
Monthly Monthly Quarterly 












No. of injections in 
maintenance phase 
9 9 3 
9 for control 
3 for study 
Table 1. Summary table of many different treatment regimen. 
The current norm in clinical practice with ranibizumab or bevacizumab is to implement an 
initiation/induction phase followed by an individualized maintenance phase that is 
modeled after one of two basic approaches: traditional PRN [32] or ‘treat and extend’ [33, 
34]. Traditional PRN involves both regular follow-up and treatment until the macula is more 
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or less free of exudation, with treatment thereafter during the maintenance phase only in the 
presence of recurrent exudation. The original prospective studies that evaluated a PRN 
approach to the maintenance phase were the Prospective Optical Coherence Tomography 
Imaging of Patients with Neovascular AMD Treated with Intra-Ocular Lucentis (PrONTO) 
study [35] and the Secondary to Age-Related Macular Degeneration (SAILOR) study [36]. 
More recently, the Study of Ranibizumab in Patients with Subfoveal Choroidal 
Neovascularization Secondary to Age-Related Macular Degeneration (SUSTAIN) study has 
contributed additional data [37]. In each of these trials, patients received three consecutive, 
monthly intravitreal injections of ranibizumab for induction, followed by monthly office 
visits. Thereafter, a PRN maintenance phase adhered to the following retreatment criteria: 
loss of at least five ETDRS letters, increase in central macular thickness on OCT of at least 
100μm, or new hemorrhage.  
Of the three studies, the PrONTO study demonstrated the best VA results. The PrONTO 
study evaluated an OCT guided, variable-dosing regimen with ranibizumab (0.5 mg) and 
showed that mean VA improved by 9.3 ETDRS letters at 12 months. Over a 2-year period, 
mean BCVA outcomes were similar to MARINA and ANCHOR with a mean of 9.9 
injections (5.6 in the first year and 4.3 in the second). In comparison, results from the 
SAILOR study were not as good. In this study, the mean change in BCVA at 12 months from 
baseline was 0.5 and 1.7 letters in the treatment-naive and previously treated groups, 
respectively, at the 0.3 mg dose and 2.3 letters in both groups at 0.5 mg. It is worth noting 
that participants were not monitored as closely in SAILOR as compared with PrONTO, 
averaging nine visits through 1 year and a mean of 4.9 injections.  
The 12-month results from SUSTAIN were slightly better than those from SAILOR (mean 
BCVA from baseline of 3.6 letters), yet still not as good as the monthly treatment trials. In 
contrast to SAILOR, participants in the SUSTAIN trial were followed monthly (more like 
PrONTO) and the mean number of injections over the first year was higher at 5.6.  
Other relatively large studies using a traditional PRN approach have recently been 
published [38-40]. An analysis of these reports highlights an important trend: the best visual 
acuity results come from the study with the greatest mean number of treatments and closest 
follow-up, whereas the poorest outcomes were observed in the study with the lowest mean 
number of treatments and office visits. Unlike traditional PRN, a treat and extend approach 
initially involves regular and frequent treatment until the macula is dry, followed by a 
gradual extension of the treatment interval and corresponding follow-up visit. Treatment 
interval extension continues until there are signs of recurrence, at which point the treatment 
interval is then reduced.  
Kang et al. [41, 42] recently published a retrospective analysis that monthly injections were 
not given in contrast to the three injections during the initial treatment period in the PIER 
and PrONTO trials. This study showed that visual acuity improved by 0.078 logMAR units 
and minimized the number of injections given during 12 months of follow-up (a mean of 
4.07 injections were given over the 12 months). The decreased need for retreatment is of 
great benefit to both patients and clinicians. These results may raise doubts about the need 
for the three initial loading injections. They reported another study [42], the mean number of 
injections given in the 12 months period was 4.2 (range, 1-6). Patients were also offered 
reinjection with ranibizumab on an “as needed” basis. Data showed that the percentage of 
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patients (71.9%) with no visual loss or improved visual acuity was comparable to the 
percentages in the monthly injection-based studies.  
In addition, Gupta et al. evaluated a treat and extend approach with bevacizumab and 
found nearly identical results at 12 months following a mean of 7.3 injections in the first year 
[40]. Although various methods for individualizing maintenance therapy have been 
proposed, the optimal non-monthly dosing regimen still remains unclear.  
4. Combination therapy: Photodynamic therapy and antivascular endothelial 
growth factor therapy 
The development and propagation of CNV membranes involve pro-angiogenic factors, 
vascular permeability molecules, and inflammatory proteins. Current standard treatment 
with monthly intravitreal injections of anti-VEGF monotherapy can be limited to the 
angiogenic component of CNV development and burdensome for both the physician and 
patient. Patients are subjected to increased risk of adverse effects from monthly 
treatments that may be lessened with treatment options given with less frequency [43]. 
While current monotherapy with anti-VEGF agents are effective therapy for CNV, their 
benefits are short-lived as they are unable to regress the lesions completely. Combination 
therapy with PDT proven to be effective in CNV regression may have a role not only in 
the treatment of CNV development but also may provide synergy through blocking 
adverse effects.  
PDT was approved in 2000 by the FDA for the treatment of CNV secondary to AMD. 
Treatment involves intravenous administration of a light-sensitive dye called verteporfin 
followed by laser-guided, location-specific activation within the CNV membrane. Activation 
of the verteporfin molecules incite a phototoxic event within blood vessels, induce 
endothelial cell damage, platelet aggregation, and eventually lead to thrombosis of vascular 
channels. Treatment size is limited by the greatest linear diameter of the CNV lesion being 
treated [44, 45].  
Variable factors within PDT treatment regimens include time of laser application and laser 
fluence. Standard fluence PDT (sfPDT) was commonly employed in the early studies. The 
Treatment of AMD with PDT (TAP) study showed stabilization but no improvement in vision 
with this protocol. In addition, other studies have reported that PDT may inadvertently 
perturb the normal choriocapillaris bordering a pathologic CNV lesion, resulting in  
up-regulation and expression of VEGF [46, 47]. This collateral damage may potentially be 
minimized with reduced-fluence PDT (rfPDT) [46]. rfPDT protocols have gained popularity 
because of its potential for increased CNV membrane selectivity and propensity to cause less 
surrounding retinal inflammation. The Verteporfin in Minimally Classic (VIM) trial employed 
both a standard and reduced fluence PDT protocol and showed stability of vision with either 
treatment over placebo, but it showed a clear trend toward a better visual outcome with 
rfPDT. In another comparative study, patients treated with rfPDT tended to have lower rates 
of severe visual loss and an overall better visual prognosis [46]. 
While PDT is intended to specifically target CNV vessels, collateral damage to surrounding 
blood vessels may lead to ischemia of healthy tissue. Following PDT of a CNV membrane, 
induced ischemia can lead to production of pro-angiogenic factors, especially VEGF. 
Therefore, combining verteporfin PDT and anti-VEGF therapy may be beneficial compared 
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with either modality alone, yielding longer treatment-free intervals and requiring fewer 
intravitreal injections [44].  
The RhuFab V2 Ocular Treatment Combining the Use of Visudyne to Evaluate Safety (FOCUS) 
study is a multicenter, randomized, single-blind study designed to evaluate the safety and 
efficacy of sfPDT in combination with intravitreal ranibizumab [48, 49]. It compared sfPDT to 
combination sfPDT and intravitreal ranibizumab in the treatment of predominantly classic 
CNV secondary to AMD. One-year data showed greater visual stability in the patients treated 
with combination therapy and 23.8% of patients experienced improvement in visual acuity, 
compared with 5% of patients treated with PDT monotherapy alone. The number of re-
treatments with sfPDT were decreased as well with 91% of patients treated with sfPDT 
monotherapy requiring repeat treatment while only 28% of patients treated with combination 
therapy requiring re-treatment within one year. Two-year data showed similar results with 
88% of combination treated patients losing less than 15 lines of vision versus 75% of sfPDT 
alone treated patients. Combination therapy required an average of 0.4 repeat PDT treatments 
compared with an average of 3.0 in the sfPDT group [49].  
5. Vascular endothelial growth factor Trap-Eye 
The most effective dosing regimen and monitoring program for anti-VEGF therapy has yet 
to be firmly established but new treatments are aimed at extending and improving on the 
efficacy of ranibizumab. VEGF Trap-Eye (aflibercept, Regeneron Pharmaceuticals, USA) is a 
promising new anti-VEGF drug. Structurally, VEGF Trap-Eye is a fusion protein of key 
binding domains of human VEGF receptor 1 and 2 combined with a human IgG Fc 
fragment. Functionally, VEGF Trap-Eye acts as a receptor decoy with high affinity for all 
VEGF isoforms, binding more tightly. VEGF Trap-Eye differs from established anti-VEGF 
therapies in its higher binding affinity for VEGF-A and its blockage of placental growth 
factors-1 and -2 [50, 51].  
Recently, the 1 year results of two parallel randomized, double-masked phase 3 clinical 
trials (VIEW 1 and VIEW 2) on the efficacy and safety of VEGF Trap-Eye for the treatment of 
neovascular AMD were reported [51]. Phase I data demonstrated acceptable safety and 
tolerability of VEGF Trap-Eye in the treatment of neovascular AMD. In Phase II study data, 
patients dosed in a similar fashion to the PrONTO trial demonstrated stabilization of their 
vision that was similar to previous studies of ranibizumab at 1 year. All dosing regimens of 
VEGF Trap-Eye, including 2 mg bimonthly met the primary endpoint of non inferiority 
compared with monthly 0.5 mg ranibizumab with regard to the percentage of patients with 
maintenance (loss of <15 ETDRS letters) or improvement in vision. The all treatment groups 
showed a mean gain of 5.3 letters at 1 year. A greater mean improvement in VA compared 
with monthly 0.5 mg ranibizumab at 1 year versus baseline represented the secondary 
endpoint of the study. In both the North American study (VIEW 1) and international study 
(VIEW 2), more than 95% of patients in each of the following VEGF Trap-Eye dosing groups 
achieved maintenance of vision compared with 94% of patients on monthly ranibizumab: 
0.5 mg monthly, 2 mg monthly, and 2 mg every 2 months. In VIEW 1, patients on 2 mg 
monthly dosing achieved the secondary endpoint with a mean gain of 10.9 ETDRS letters 
compared with 8.1 for monthly ranibizumab [51].  
The results of the VIEW studies come at a critical time, when clinical evidence suggests that 
less frequent dosing of existing anti-VEGF therapy, particularly in the first year, may yield 
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inconsistent visual acuity outcome. In particular, the ability to achieve maintenance or 
improvement in VA with a more convenient every-other-month injection without need for 
intervening office visits may potentiate a shift in the current management of neovascular 
AMD. Continuation of the VIEW studies through the second year will assess the various 
VEGF Trap-Eye doses administered every 3 months, or more often in the case of worsening 
disease, as per protocol-defined ‘quarterly capped PRN’ schedule. Based on phase II data, 
VEGF Trap-Eye seems to be generally well tolerated with no serious drug-related adverse 
events. In the 157 patients enrolled in phase II trial, there were two deaths (one from pre-
existing pulmonary hypertension and one from pancreatic carcinoma) and one arterial 
thromboembolic events (patient with a history of previous stroke), but no serious systemic 
events occurred related to VEGF Trap-Eye [51].  
In contrast to current anti-VEGF antibodies, which are rapidly cleared, the VEGF Trap-Eye 
is relatively degraded more slowly. Due to its high binding affinity and the ability to safely 
inject high doses into the eye, VEGF Trap-Eye may have longer duration of effect in the eye. 
Its adoption into clinical practice will depend on efficacy at 4 and 8 week intervals. If 
effective at 4 and 8 week intervals, VEGF Trap-Eye may offer a competitive price advantage 
over ranibizumab and the opportunity to significantly reduce treatment burden on patients 
and physicians.  
6. Conclusion  
Blindness secondary to AMD is common across the world and the pathogenesis of this 
severe condition is not fully understood. However, the advent of anti-VEGF therapy has 
revolutionized therapy in the management of neovascular AMD. The appropriate method, 
dose, regimen, types of combination therapy, and the safety of anti-VEGF remain to be 
investigated but randomized trials are pending and may provide a clearer answer, which 
hopefully can help in the treatment of resistant CNV with longer time between treatments.  
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